Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments
Advanced Healthcare Materials · 2024-04 · 13 (11)
DOI: 10.1002/adhm.202303561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 10.12.2023. Verfasst von Aurino M Kemas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, 17177, Sweden. Hauptthemen laut MEDLINE: Polymers. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet.
Abstract (Originalsprache)
Organotypic and microphysiological systems (MPS) that can emulate the molecular phenotype and function of human tissues, such as liver, are increasingly used in preclinical drug development. However, despite their improved predictivity, drug development success rates have remained low with most compounds failing in clinical phases despite promising preclinical data. Here, it is tested whether absorption of small molecules to polymers commonly used for MPS fabrication can impact preclinical pharmacological and toxicological assessments and contribute to the high clinical failure rates. To this end, identical devices are fabricated from eight different MPS polymers and absorption of prototypic compounds with different physicochemical properties are analyzed. It is found that overall absorption is primarily driven by compound hydrophobicity and the number of rotatable bonds. However, absorption can differ by >1000‐fold between polymers with polydimethyl siloxane (PDMS) being most absorptive, whereas polytetrafluoroethylene (PTFE) and thiol‐ene epoxy (TEE) absorbed the least. Strikingly, organotypic primary human liver cultures successfully flagged hydrophobic hepatotoxins in lowly absorbing TEE devices at therapeutically relevant concentrations, whereas isogenic cultures in PDMS devices are resistant, resulting in false negative safety signals. Combined, these results can guide the selection of MPS materials and facilitate the development of preclinical assays with improved translatability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, 17177, Sweden.
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376, Stuttgart, Germany.
- University of Tuebingen, 72074, Tuebingen, Germany.
- Division of Micro- and Nanosystems, KTH Royal Institute of Technology, Stockholm, 10044, Sweden.
- Department of Oncology and Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, 17165, Sweden.
- Department of Drug Metabolism and Pharmacokinetics (DMPK), Merck KGaA, 64293, Darmstadt, Germany.
ORCID-Profile: Volker M Lauschke
Förderung
- Horizon 2020 Framework Programme
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet
Zitieren
APA
Kemas, A. M., Zandi Shafagh, R., Taebnia, N., Michel, M., Preiss, L., Hofmann, U., & Lauschke, V. M. (2024). Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments. Advanced Healthcare Materials, 13(11). https://doi.org/10.1002/adhm.202303561
Vancouver
Kemas AM, Zandi Shafagh R, Taebnia N, Michel M, Preiss L, Hofmann U, et al. Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments. Advanced Healthcare Materials. 2024;13(11). doi:10.1002/adhm.202303561
BibTeX
@article{Kemas2024,
author = {Kemas, Aurino M and Zandi Shafagh, Reza and Taebnia, Nayere and Michel, Maurice and Preiss, Lena and Hofmann, Ute and Lauschke, Volker M},
title = {Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {11},
doi = {10.1002/adhm.202303561}
}
EUVIMED